SCHEMBL2883485

SCHEMBL2883485

CCOC(=O)c1ncc2nc(-c3cncc(Br)c3)sc2c1O

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.41
HDAC6 Q9UBN7 1/20 0.41
CDC7 O00311 11/20 0.40
DBF4 Q9UBU7 11/20 0.40
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
NFKB1 P19838 1/20 0.40
RAB9A P51151 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
TRPM8 Q7Z2W7 6/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2884453 0.86 CDC7 (0.41) CDC7DBF4MAPTALDH1A1TRPM8
SCHEMBL2884449 0.82 CDC7 (0.57) SMN1; SMN2CDC7DBF4MAPTKDM4E
SCHEMBL2880781 0.81 CDC7 (0.56) SMN1; SMN2CDC7DBF4MAPTNPC1
SCHEMBL2884015 0.80 TRPM8 (0.42) SMN1; SMN2CDC7DBF4MAPTKDM4E
SCHEMBL2886810 0.80 TRPM8 (0.58) SMN1; SMN2CDC7DBF4MAPTKDM4E
SCHEMBL2880807 0.80 TRPM8 (0.58) CDC7DBF4MAPTKDM4ENPC1
SCHEMBL2883896 0.80 TRPM8 (0.54) SMN1; SMN2CDC7DBF4MAPTNPC1
SCHEMBL2885106 0.79 NPC1 (0.43) SMN1; SMN2CDC7DBF4MAPTKDM4E
SCHEMBL2887515 0.79 PTPN11 (0.51) CDC7DBF4MAPTKDM4ENPC1
SCHEMBL2881042 0.78 EGLN1 (0.45) HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3124489-B1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2020-07-15 EP disclosed
EP-3124489-A1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS Fibrogen, Inc. (US) 2017-02-01 EP disclosed
EP-2016078-B1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2016-06-15 EP disclosed
US-7696223-B2 [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) FIBROGEN, INC. (US) 2010-04-13 US disclosed
EP-2016078-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2009-01-21 EP disclosed
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. 2008-01-03 US disclosed
WO-2007115315-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 SMN1; SMN2 3919/4885HDAC6 714/4885CDC7 2482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.